Dronedarone hydrochloride in atrial fibrillation - horizon scanning review
NHSC
Record ID 32005000259
English
Authors' objectives:
This study aims to assess the effectiveness of dronedarone hydrochloride in atrial fibrillation (AF).
Authors' recommendations:
Dronedarone hydrochloride (SR33589B) is an antiarrhythmic drug in phase III trials to prevent recurrence of atrial fibrillation (AF) and to control ventricular rate. It is structurally similar to amiodarone but reportedly has a better adverse effect and drug interaction profile. Interim results from two unpublished, phase III, randomised, placebo-controlled trials show a significant increase in time to first recurrence of AF in patients with paroxysmal AF. A published phase II trial showed a significant increase in time to first recurrence of AF in patients with persistent AF following cardioversion.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Anti-Arrhythmia Agents
- Atrial Fibrillation
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.